Latest filing published 02 May 2013 for HAEMONETICS CORP, €15k.
Insider track record
No signal scores available.
Closed purchases
Based on 7 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -19.2%Entry US$38.81 · Close at T+365 US$31.34
- +6.2%Entry US$33.63 · Close at T+365 US$35.72
- -0.7%Entry US$29.39 · Close at T+365 US$29.17
- +19.6%Entry US$28.11 · Close at T+365 US$33.63
- -7.1%Entry US$27.49 · Close at T+365 US$25.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Joseph J. Forish: trading record in brief
Joseph J. Forish is a declared insider of Haemonetics Corp, with filings sourced from SEC (Form 4). Over a trading history stretching from 1 November 2006 to 30 April 2013, the count stands at 45 filings.
Market trades split into 10 purchases (€135k) and 11 sales (€4.8M). Taken together, the sales exceed the purchases by €4.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 6 share grants and 8 option exercises. So far in 2013, the count stands at 1 purchase and no sales.
The median purchase comes to €14k. Ninety days after publication, 7 purchases show a median change of +2.4%, with the price up in 57% of them. This is a record of the past, not a forecast.
The newest entry dates from 2 May 2013: an open-market purchase of €15k, in Haemonetics Corp. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Joseph J. Forish
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 615 shares@ US$32.73Common StockSEC:0000313143-13-000075:0Canonical exit: 29 Jul 2013 (T+90)
- 99 shares@ US$76.33Common StockSEC:0000313143-12-000206:0
- 384 shares0Common StockSEC:0000313143-12-000173:0
- 79 shares@ US$78.04Common StockSEC:0000313143-12-000158:0
- 5,373 shares@ US$52.76Common StockSEC:0001325812-12-000023:0
- 5,373 shares@ US$80.00Common StockSEC:0001325812-12-000023:1
- 5,000 shares@ US$52.76Common StockSEC:0000313143-12-000093:0
- 5,000 shares@ US$74.00Common StockSEC:0000313143-12-000093:1
- 12,000 shares@ US$48.20Common StockSEC:0000313143-12-000091:0
- 12,000 shares@ US$71.14Common StockSEC:0000313143-12-000091:1
- 14,000 shares@ US$48.20Common StockSEC:0000313143-12-000088:0
- 14,000 shares@ US$72.35Common StockSEC:0000313143-12-000088:1
- 13,000 shares@ US$48.20Common StockSEC:0000313143-12-000089:0
- 13,000 shares@ US$72.23Common StockSEC:0000313143-12-000089:1
- 11,000 shares@ US$48.20Common StockSEC:0000313143-12-000089:2
- 11,000 shares@ US$72.40Common StockSEC:0000313143-12-000089:3
- 21,748 shares@ US$48.20Common StockSEC:0000313143-12-000057:0
- 21,748 shares@ US$72.00Common StockSEC:0000313143-12-000057:1
- 3,252 shares@ US$48.20Common StockSEC:0000313143-12-000039:0
- 3,252 shares@ US$72.00Common StockSEC:0000313143-12-000039:1
- 426 shares@ US$49.83Common StockSEC:0000313143-12-000039:2Canonical exit: 30 Jul 2012 (T+90)
- 79 shares@ US$59.16Common StockSEC:0000313143-11-000128:0
- 151 shares@ US$59.03Common StockSEC:0000313143-11-000128:1
- 60 shares@ US$60.41Common StockSEC:0000313143-11-000084:0
- 60 shares@ US$61.03Common StockSEC:0000313143-11-000084:1
25 of 40 declarations
